CN103948754A - Drug for treating renal-deficiency humid-heat type chronic nephritis - Google Patents
Drug for treating renal-deficiency humid-heat type chronic nephritis Download PDFInfo
- Publication number
- CN103948754A CN103948754A CN201410206252.XA CN201410206252A CN103948754A CN 103948754 A CN103948754 A CN 103948754A CN 201410206252 A CN201410206252 A CN 201410206252A CN 103948754 A CN103948754 A CN 103948754A
- Authority
- CN
- China
- Prior art keywords
- kidney
- parts
- deficiency
- group
- chronic nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug for treating renal-deficiency humid-heat type chronic nephritis. The drug is prepared from the following material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 8-12 parts of white atractylodes rhizome, 8-12 parts of pulp of dogwood fruit, 10-30 parts of eucommia ulmoides, 10-20 parts of rhizoma alismatis, 10-30 parts of herba pyrrosiae, 10-30 parts of oldenlandia diffusa and 3-7 parts of pseudo-ginseng. After being proved by a pharmacological experiment, the drug disclosed by the invention has a better function in treating chronic nephritis, is safe to take, suitable for preventing and treating chronic nephritis. The invention further discloses a preparation method and an application of the drug.
Description
Technical field
The invention belongs to Chinese medicine composition technical field, in particular, relate to a kind of Chinese medicine formula medicine for the treatment of chronic nephritis and its preparation method and application.
Background technology
Chronic nephritis is common nephropathy, and the situation that prevalence is high, case fatality rate is high is very serious, and its sickness rate is the trend rising year by year.Chronic nephritis is to be caused by many reasons, pathological change differs, its main manifestations is edema, albuminuria, hematuria, and hypertension and decreased renal function, in traditional Chinese medical science ancient books, do not have " chronic glomerulonephritis " this name of disease, but according to its clinical manifestation and characteristics of incidence, this disease belongs to the categories such as " edema " in Chinese medicine, " lumbago ", " the kidney-wind syndrome ", " difficulty in urination ", " obstruction and rejection ", " impairment of the kidney caused by overstrain ", " asthenia ", " poison of drowning ", " hematuria ".Sick position is mainly at spleen, kidney.The traditional Chinese medical science thinks that The spleen has the function to transport and transform nutrients, and separating clear and excreting turbid completes absorption and the transporting of essence of water and grain, participates in the metabolism of body water liquid; Spleen governing blood moves blood in vascular, prevents outside blood oozing from the body openings or subcuta neous tissue arteries and veins.Kidney governing storage, hides nephroyin and nephroyang; The main water of kidney, completes the metabolism of water liquid.If there is pathology damage, deficiency of spleen and stomach, spleen loses transporting, precise and tinyly cannot normally absorb, transporting; Kidney loses envelope and hides, and precise and tinyly leaks into urine and occurs albuminuria outward; Spleen loses and has under one's command, escape of blood from meridians, and blood oozing from the body openings or subcuta neous tissue arteries and veins enters urine outward and hyperamization urine; Spleen loses transporting, retention of water-damp in the body, and skin overflows; Kidney unit is not enough, and bladder loses in gasification, and it is entire unfavorable to open, and retention of water-damp in the body forms the disease of edema.Clinical observation is visible, and primary disease pathogenic factor is mainly that damp and hot, blood stasis, turbid poison, water are wet.Therefore primary disease pathogenesis is deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive.Kidney disease is not only quite common, and medical expense is very high, uremic patient dialysis expense for each person every year needs ten thousand yuans of 5-6, high medical expense is brought very heavy financial burden to patient and society, and chronic nephritis is still the first cause of disease that China causes Uremia Dialysis at present, so active treatment chronic nephritis is significant.
At present, western medicine and medical practitioners treatment nephritis mainly adopts hormone, immunosuppressant, ACEI/ARB class medicine etc., and its course for the treatment of is very long, is easy to knock-on after drug withdrawal, and side effect is also many, and patient compliance is poor.Market in urgent need is a kind of widely applicable, the suffer from a deficiency of the kidney Chinese medicine preparation of damp-heat type chronic nephritis of the little treatment of side effect.
Summary of the invention
The object of the present invention is to provide a kind of evident in efficacy, the little treatment of the side effect Chinese medicine preparation of damp-heat type chronic nephritis and preparation method thereof of suffering from a deficiency of the kidney.
The present invention is achieved through the following technical solutions:
A medicine that is used for the treatment of the damp-heat type chronic nephritis of suffering from a deficiency of the kidney, the crude drug of pressing row weight portion proportioning extracts and is prepared from: Radix Astragali 20-40 part; Rhizoma Atractylodis Macrocephalae 8-12 part; Fructus Corni 8-12 part; Cortex Eucommiae 10-30 part; Rhizoma Alismatis 10-20 part; Folium Pyrrosiae 10-30 part; Herba Hedyotidis Diffusae 10-30 part; Radix Notoginseng 3-7 part.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of, the crude drug of pressing row weight portion proportioning extracts and is prepared from: 30 parts of the Radixs Astragali; 10 parts of the Rhizoma Atractylodis Macrocephalaes; 10 parts of Fructus Corni; 20 parts of the Cortexs Eucommiae; 15 parts of Rhizoma Alismatis; 20 parts of Folium Pyrrosiae; 20 parts of Herba Hedyotidis Diffusaes; 5 parts of Radix Notoginseng.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of, preparation method comprises the following steps:
A) by above-mentioned parts by weight, get the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae two tastes are through extraction by steam distillation volatile oil, with beta-cyclodextrin inclusion compound;
B) by above-mentioned parts by weight, get the Radix Astragali, the Cortex Eucommiae, Rhizoma Alismatis, Folium Pyrrosiae, the Radix Notoginseng five tastes, through alcohol reflux, filter, and reclaim ethanol, concentrate to obtain alcohol extraction concentrated solution;
C) medicinal residues after the medicinal residues after step a steam distillation, b alcohol extraction and Fructus Corni are merged, through decocting, boil, filter, concentrated, cooling, add ethanol precipitate with ethanol and obtain water extract-alcohol precipitation concentrated solution; The alcohol extraction concentrated solution of water extract-alcohol precipitation concentrated solution and step b is merged, and spraying is dry, makes dry extract;
D) get the volatile oil clathrate compound of step a and the dry extract of c carries out wet granulation, dry, obtain medicine.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of, steam distillation in preparation method step a, use 6 times of water gagings of medical material weight to soak 1 hour, distill and within 8 hours, extract volatile oil, volatile oil adds 6 times of weight beta-schardinger dextrin-s, adopts 40 ℃ of electric stirrings of saturated water solution method, and mixing speed is 120r/min, stir and carry out enclose after 1.5 hours, 40 ℃ of vacuum dryings of clathrate.
The above-mentioned treatment damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney, alcohol reflux in preparation method step b, institute's alcohol adding amount is 12 times of decoction pieces gross weight, ethanol volumetric concentration is 70%, divide three reflux, extract,, each 2 hours, merge extractive liquid,, filter, decompression filtrate recycling ethanol, is concentrated into without alcohol taste.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of, in preparation method step c, through decocting, boil, amount of water is 12 times of decoction pieces gross weight, divide secondary to decoct, each 2 hours, merge decocting liquid, filter, when filtrate is concentrated into 50 ℃, relative density is 1.05～1.08, cooling, add ethanol to alcohol content and be no more than 50%, stir evenly, place 48 hours, filter, filtrate recycling ethanol, while being concentrated into 50 ℃ with above-mentioned alcohol extraction concentrated solution merging, relative density is 1.10～1.15, add dextrin appropriate, in import pathogenic wind-warm, it is 165～175 ℃, under 85～90 ℃ of conditions of outlet pathogenic wind-warm, be spray dried to dry extract.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of, in preparation method steps d, get and in step a volatile oil clathrate compound and step c, get that dry extract adds appropriate Icing Sugar, dextrin mixes and carries out wet granulation, dry, obtain medicine, dosage form is tablet or granule or hard capsule.
The above-mentioned damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of is treated the application of suffering from a deficiency of the kidney in damp-heat type chronic nephritis medicine in preparation.
In the present invention, the Rhizoma Atractylodis Macrocephalae is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz., the Radix Astragali is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.Var.mongholicus (Bge.) Hsiao, Fructus Corni is Cornaceae plant Fructus Corni Comus officinalis Sieb.et Zucc. drying and ripening sarcocarp, the Cortex Eucommiae is the dry bark of Eucommiaceae plant Cortex Eucommiae Eucommia ulmoides Oliv., Rhizoma Alismatis is the dry tuber of Notes On Alism At Aceae Rhizoma Alismatis Alisma orientalis (Sam.) Juzep., Radix Notoginseng is the dry root of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen, Folium Pyrrosiae is the dried leaves of Plants of Polypodiaceae Folium Pyrrosiae Pyrrosia lingua (Thunb.) Farwell, Herba Hedyotidis Diffusae is the dry herb of Maguireothamnus speciosus Herba Hedyotidis Diffusae Hedyotis diffusa Willd..
The present invention compares with the Chinese medicine of existing treatment chronic nephritis, has following advantages:
(1) in side, Radix Astragali, Fructus Corni are monarch drug.Radix Astragali sweet in the mouth, slightly warm in nature, has benefiting qi and raising yang, invigorating spleen for diuresis, benefit is defended the merit of consolidating superficial resistance.Modern pharmacological research confirms that it has stronger immunoregulation effect, can promote the lymphocytic differentiation of T with ripe, and inducing cell produces interferon, can remove vasospasm simultaneously, improve microcirculation, strengthen and organize hypoxia-bearing capability, reduce the effects such as effect such as albuminuria, diuresis.Fructus Corni sweet in the mouth, micro-hardship, enters Liver and kidney warp, has invigorating the liver and kidney, and the merit of arresting seminal emission gas has protection and increases strong function of depositing nephron.It is common pattern of syndrome that the common chronic nephropathys such as chronic nephritis, diabetic nephropathy, chronic pyelonephritis be take spleen deficiency of kidney-QI and deficiency of both QI and YIN, thus air making-up and spleen enlivening, the conventional rule for the treatment of that replenishing YIN to strengthen the kidney is chronic nephropathy.Radix Astragali, Fructus Corni one air making-up and spleen enlivening in side, one enriching yin and nourishing kidney, amount to supplementing QI and nourishing YIN, and the merit of reinforce spleen and kidney together, is all monarch drug.In side, the Rhizoma Atractylodis Macrocephalae, the Cortex Eucommiae are ministerial drug.Rhizoma Atractylodis Macrocephalae sweet in the mouth, hardship, warm in nature, tool air making-up and spleen enlivening, the merit of dampness diuretic, due to the edema common sympton of chronic nephritis still, and the disease of edema, " the fundamental cause of water disease being in the kidney ", " it is built in spleen ", the Rhizoma Atractylodis Macrocephalae both can help the Radix Astragali with QI invigorating, again can removing dampness activating the spleen in case the Radix Astragali is stopped up air resister.Cortex Eucommiae sweet in the mouth, micro-pungent, warm in nature, enter Liver and kidney two warps, there is liver and kidney tonifying, the merit of strong muscles and bones, is usually used in treating the soreness of waist and knee joint of deficiency of the liver and kindey, and sufficient knee joint flaccidity is soft unable, and in side, the Cortex Eucommiae helps Fructus Corni invigorating kidney qi, is ministerial drug.In side, Rhizoma Alismatis, Folium Pyrrosiae, Herba Hedyotidis Diffusae, Radix Notoginseng are adjuvant drug altogether.Rhizoma Alismatis slightly sweet flavor, cold in nature, energy promoting diuresis to eliminate damp pathogen, expels the heat-evil treating stranguria.Cure mainly functioning of bladder unfavorable, water is wet to stop gathering, dysuria, and edema distension, pharmacological research proof Rhizoma Alismatis can blood pressure lowering, the excretion of blood sugar lowering, blood fat reducing, increase urine amount, carbamide and sodium chloride.Folium Pyrrosiae sweet-bitter flavor, cold nature, energy relieving stranguria by diuresis, clearing away heat to stop bleeding.The disease such as pyretic stranguria, stranguria with blood, hematuria that is usually used in damp-heat in lower-JIAO.Pharmacological research shows, Folium Pyrrosiae has antiinflammatory and resisting pathogenic microbes and diuresis, clinically can be used for treating acute and chronic nephritis, pyelonephritis, except eliminating edema, also has minimizing albuminuria, improves renal function effect.Herba Hedyotidis Diffusae slightly sweet flavor, cool in nature, energy heat-clearing and toxic substances removing, promoting blood circulation and detumescence, cures mainly furuncle carbuncle, laryngopharynx swelling and pain, damp-heat in lower-JIAO.Modern pharmacology research finds that it has the effect of stronger resisting pathogenic microbes, can stimulate reticuloendothelial system hypertrophy, increase cytophagous phagocytic activity, the defence capability of enhancing body.And at patients with chronic glomerulonephritis, lung kidney two through damp and hot be its Relapse rate or the common cause that increases the weight of, though the merit of Herba Hedyotidis Diffusae tool heat-clearing and toxic substances removing, the anxiety that its property slightly sweet flavor injures one's stomach without bitter cold.Due to common retention of damp-heat in the interior in chronic kidney disease mark excess syndrome, and damp and hot is multiple chronic kidney disease Relapse rate or the key factor that increases the weight of, therefore eliminating damp-heat is the conventional rule for the treatment of of chronic nephropathy.In side, Rhizoma Alismatis, Folium Pyrrosiae, Herba Hedyotidis Diffusae three medicines share and reach heat-clearing and toxic substances removing, inducing diuresis and reducing edema merit.Radix Notoginseng sweet and slightly bitter taste, warm in nature, the hemostasis of raw product function dissipating blood stasis, reducing swelling and alleviating pain, hemostasis and do not stay the stasis of blood.For multiple hemorrhagic condition and treating swelling and pain by traumatic injury.Modern pharmacology research finds that it has the thrombin increasing in blood, and local vascular is shunk, thereby reaches anastalsis.And the total Saponin energy of Radix Notoginseng anticoagulant, experiment in vitro has anticoagulant active.The coagulant of visible Radix Notoginseng and anticoagulant dual regulation think that with the traditional Chinese medical science its promoting blood circulation and hemostasis effect conforms to.Chronic nephropathy is common hematuria clinically, it is the intrinsic cell proliferation of multiple kidney that Pathological changes modal performance, and often with glomerular sclerosis and kidney region fibrosis, both tool hemostasis of Radix Notoginseng, invigorate blood circulation again and do not stay stasis of blood effect to be just applicable to multiple chronic nephropathy.The present invention is improving patient clinical symptom, renal function protecting, and safety aspect has good advantage.The traditional Chinese medical science think chronic nephritis main clinical manifestation, test rating often to suffer from a deficiency of the kidney damp and hot relevant, belong to Primary Asthenia-Secondary Sthenia Syndrome, spleen deficiency of kidney-QI is this, hot and humid ecchymosis is mark, its effect of compatibility of the present invention is tonifying speen and tonifying kidney, boosting qi and nourishing yin, eliminating damp-heat, cure mainly chronic glomerulonephritis spleen kidney qi Yin bivacuity, retention of damp-heat in the interior card.
(2) Chinese medicine is mostly decoction at present, and recipe quantity is large, flavour of a drug are many, use inconvenience, and the present invention has good defencive function to chronic nephritis;
(3) preparation technology is simple, and extraction efficiency is high, cost-saving;
(4) medicine of the present invention can be made into the dosage forms such as granule, capsule, tablet or pill, taking convenience;
(5) the present invention shows through clinical and pharmacological tests; this Chinese medicine preparation can significantly improve clinical card marquis, reduction urine protein, reduction serum creatinine, urea nitrogen levels, inflammation-inhibiting reaction and inflammatory mediator release; promote the reparation of glomerule pathology infringement; thereby chronic nephritis is had to good therapeutical effect; be developed to the new drug that chronic nephritis is had to assistant protection function health product or treatment chronic nephritis; its market capacity is large, and economic benefit and social benefit are obvious.
The specific embodiment
Embodiment 1:
Get Radix Astragali 200g; Rhizoma Atractylodis Macrocephalae 120g; Fructus Corni 80g Cortex Eucommiae 300g; Rhizoma Alismatis 100g; Folium Pyrrosiae 300g; Herba Hedyotidis Diffusae 100g; Radix Notoginseng 70g,
A. get the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae two tastes are through extraction by steam distillation volatile oil, use 6 times of water gagings of medical material weight to soak 1 hour, distill and within 8 hours, extract volatile oil, volatile oil adds 6 times of weight beta-schardinger dextrin-s, adopts 40 ℃ of electric stirrings of saturated water solution method, and mixing speed is 120r/min, stir and carry out enclose after 1.5 hours, 40 ℃ of vacuum dryings of clathrate.
B. get the Radix Astragali, the Cortex Eucommiae, Rhizoma Alismatis, Folium Pyrrosiae, the Radix Notoginseng five tastes, through alcohol reflux, institute's alcohol adding amount is 12 times of decoction pieces gross weight, and ethanol volumetric concentration is 70%, minute three reflux, extract,, each 2 hours, merge extractive liquid,, filters, and decompression filtrate recycling ethanol, is concentrated into without alcohol taste.Filter, reclaim ethanol, concentrate to obtain alcohol extraction concentrated solution;
C. by the medicinal residues after step a steam distillation, medicinal residues after step b alcohol extraction and Fructus Corni merge, through decocting, boil, amount of water is 12 times of decoction pieces gross weight, divide secondary to decoct, each 2 hours, merge decocting liquid, filter, when filtrate is concentrated into 50 ℃, relative density is 1.05, cooling, adding ethanol to alcohol content is 50%, stir evenly, place 48 hours, filter, filtrate recycling ethanol, while being concentrated into 50 ℃ with the merging of above-mentioned steps b alcohol extraction concentrated solution, relative density is 1.15, add dextrin appropriate, in import pathogenic wind-warm, it is 165 ℃, under 90 ℃ of conditions of outlet pathogenic wind-warm, be spray dried to dry extract.
D. get in step a volatile oil clathrate compound and step c and get dry extract, add appropriate dextrin and mix and carry out wet granulation, dry, tabletting, is prepared into tablet.
Embodiment 2:
Get Radix Astragali 400g; Rhizoma Atractylodis Macrocephalae 80g; Fructus Corni 120g Cortex Eucommiae 100g; Rhizoma Alismatis 200g; Folium Pyrrosiae 100g; Herba Hedyotidis Diffusae 300g; Radix Notoginseng 30g,
A. get the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae two tastes are through extraction by steam distillation volatile oil, use 6 times of water gagings of medical material weight to soak 1 hour, distill and within 8 hours, extract volatile oil, volatile oil adds 6 times of weight beta-schardinger dextrin-s, adopts 40 ℃ of electric stirrings of saturated water solution method, and mixing speed is 120r/min, stir and carry out enclose after 1.5 hours, 40 ℃ of vacuum dryings of clathrate.
B. get the Radix Astragali, the Cortex Eucommiae, Rhizoma Alismatis, Folium Pyrrosiae, the Radix Notoginseng five tastes, through alcohol reflux, institute's alcohol adding amount is 12 times of decoction pieces gross weight, and ethanol volumetric concentration is 70%, minute three reflux, extract,, each 2 hours, merge extractive liquid,, filters, and decompression filtrate recycling ethanol, is concentrated into without alcohol taste.Filter, reclaim ethanol, concentrate to obtain alcohol extraction concentrated solution;
C. by the medicinal residues after step a steam distillation, medicinal residues after step b alcohol extraction and Fructus Corni merge, through decocting, boil, amount of water is 12 times of decoction pieces gross weight, divide secondary to decoct, each 2 hours, merge decocting liquid, filter, when filtrate is concentrated into 50 ℃, relative density is 1.08, cooling, adding ethanol to alcohol content is 50%, stir evenly, place 48 hours, filter, filtrate recycling ethanol, while being concentrated into 50 ℃ with the merging of above-mentioned steps b alcohol extraction concentrated solution, relative density is 1.10, add dextrin appropriate, in import pathogenic wind-warm, it is 175 ℃, under 85 ℃ of conditions of outlet pathogenic wind-warm, be spray dried to dry extract.
D. get in step a volatile oil clathrate compound and step c and get dry extract, add appropriate dextrin and mix and carry out wet granulation, dry, be prepared into granule.
Embodiment 3:
Get Radix Astragali 300g; Rhizoma Atractylodis Macrocephalae 100g; Fructus Corni 100g Cortex Eucommiae 200g; Rhizoma Alismatis 150g; Folium Pyrrosiae 200g; Herba Hedyotidis Diffusae 200g; Radix Notoginseng 50g,
A. get the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae two tastes are through extraction by steam distillation volatile oil, use 6 times of water gagings of medical material weight to soak 1 hour, distill and within 8 hours, extract volatile oil, volatile oil adds 6 times of weight beta-schardinger dextrin-s, adopts 40 ℃ of electric stirrings of saturated water solution method, and mixing speed is 120r/min, stir and carry out enclose after 1.5 hours, 40 ℃ of vacuum dryings of clathrate.
B. get the Radix Astragali, the Cortex Eucommiae, Rhizoma Alismatis, Folium Pyrrosiae, the Radix Notoginseng five tastes, through alcohol reflux, institute's alcohol adding amount is 12 times of decoction pieces gross weight, and ethanol volumetric concentration is 70%, minute three reflux, extract,, each 2 hours, merge extractive liquid,, filters, and decompression filtrate recycling ethanol, is concentrated into without alcohol taste.Filter, reclaim ethanol, concentrate to obtain alcohol extraction concentrated solution;
C. by the medicinal residues after step a steam distillation, medicinal residues after step b alcohol extraction and Fructus Corni merge, through decocting, boil, amount of water is 12 times of decoction pieces gross weight, divide secondary to decoct, each 2 hours, merge decocting liquid, filter, when filtrate is concentrated into 50 ℃, relative density is 1.06, cooling, adding ethanol to alcohol content is 50%, stir evenly, place 48 hours, filter, filtrate recycling ethanol, while being concentrated into 50 ℃ with the merging of above-mentioned steps b alcohol extraction concentrated solution, relative density is 1.13, add dextrin appropriate, in import pathogenic wind-warm, it is 170 ℃, under 87 ℃ of conditions of outlet pathogenic wind-warm, be spray dried to dry extract.
D. get in step a volatile oil clathrate compound and step c and get dry extract, add appropriate dextrin and mix and carry out wet granulation, dry, encapsulating capsule, is prepared into hard capsule.
Embodiment 4: the present invention's (clear Zhixieli granules of kidney tonifying) pharmacological experiment:
1 materials and methods
1.1. sample: according to above-described embodiment 2 preparation the present invention, obtain dry extract.
1.2. laboratory animal: Wistar rat, body weight (150-200) g, male and female half and half, by Nanjing University of Traditional Chinese Medicine's Experimental Animal Center, provided, laboratory animal production licence number: SCXK (Soviet Union) 2008-0010, animal is divided into 5 groups at random by body weight, 10 every group.
1.3. key instrument and reagent: automatic clinical chemistry analyzer; Biochemical reagents box builds up Bioengineering Research Institute purchased from Nanjing; With distilled water, be mixed with the ethanol of 30% concentration; Hepatic tissue pathology section is made by Pathology Deparment of Jiangsu TCM Hospital.
2. the clear Zhixieli granules of kidney tonifying of the present invention is for the brightic effect of rat Heymann
The preparation of 2.1 renal cortex Freund's complete adjuvant suspensions
Get 150-200gWistar rat, de-vertebra is put to death, and speed is won kidney and inserted conduit, with normal saline, repeatedly rinses to turning white, and cuts kidney, gets that renal cortex 3g makes homogenate and Freund's complete adjuvant is mixed into 40ml, adds normal saline 40ml, and thorough emulsifying is standby.
2.2Heymann glomerulonephritis
Choose 150-200gWistar rat, after breeding observing 1w, put into metabolic cage and collect 24h urine, urine analyzer detects urine protein.Get urine protein and detect negative rat for modeling.8 rats wherein, as Normal group.All the other rats through lumbar injection renal cortex Freund's complete adjuvant suspension 2ml/ only.Same method, with dosage injection, at interval of 2w injection 1 time, inject altogether 5 times, lw after last injection, puts into respectively metabolism of rat cage by rat, collects 24h urine, biuret method is surveyed urine protein content.Urine albumen amount significantly raises and is decided to be model success index.Hank 50 of mould rats, are divided into 5 groups by randomly assigne, i.e. model group, positive drug group, tested medicine (high, medium and low) group, 10 every group.Each is organized rat and within the 9th week, starts gastric infusion in experiment, and every day, gastric infusion was 1 time, successive administration 28d, blank group, model group give normal saline, positive drug group gives shenyankangfu tablet, and tested medicine gives kidney tonifying clear Zhixieli granules extractum, and administration volume is 1mL/100g.
2.3 observation index
2.3.124h urine amount and urine protein detect: respectively at (before administration) after Cheng Mo, administration is put into metabolism of rat cage by rat in the 14th, 28 days and collected 24h urine amount, and biuret method is measured urine protein content, the results are shown in Table 1.
2.3.2BUN, GRE, total serum protein, serum albumin detect: (28d after administration) gets blood through eye socket when after Cheng Mo, (before administration), administration the 14th day and administration finish, and carries out blood biochemical detection, the results are shown in Table 2, table 3.
2.4 experimental result
The phenomenons such as 2.4.1 after the formal immunity of ordinary circumstance, the loose mixed and disorderly tarnish of lethargy, hair in various degree appears in immunized animal, it is unable to capture, loose stool, ascites.After administration, model group animal lethargy, the loose tarnish of hair increases the weight of gradually, and each group of the clear Zhixieli granules of shenyankangfu tablet group and kidney tonifying is than improvement, but still sees that spiritual beach wormwood wastes, the loose tarnish of hair.
2.4.2 urine protein dynamic change accesses urine with metabolism of rat cage, measures twenty-four-hour urine protein content.
Table 124 hour urine protein quantitation (mg/24 hour,
n=10)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 1.6076±0.8448 | 2.993±1.46 | 3.1±0.55 |
| Model group | 4.244±1.283 ** | 7.219±2.65 * | 6.94±2.40 ** |
| Shenyankangfu tablet group | 4.061±1.357 ** | 4.66±0.4 5* | 3.78±1.22 △ |
| High dose group | 4.909±1.952 ** | 5.32±0.99 * | 3.50±1.46 △ |
| Middle dosage group | 4.721±1.597 ** | 5.04±1.11 * | 4.78±1.29 * |
| Low dose group | 5.059±1.985 ** | 5.42±1.11 * | 4.38±0.909 * |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling Rat 24 h urine albumen amount significantly increase (
*p<0.01), between each group of modeling group without significant difference.Treat after 14 days, each administration group effect not significantly (with the comparison of blank group,
*p<0.05).Treat after 28 days, shenyankangfu tablet group, the clear Zhixieli granules high dose group of kidney tonifying effect is significantly (with model group comparison
△p<0.05), in the clear Zhixieli granules of kidney tonifying, low dose group effect not significantly (with the comparison of blank group,
*p<0.05).
2.4.3 serum albumin dynamic change rat eye socket is got blood, measures serum albumin.
Table 2 serum albumin (g/L,
n=10)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 33.3±2.23 | 32.68±1.41 | 32.08±2.29 |
| Model group | 28.98±2.065 ** | 26.98±2.55 ** | 26.08±2.05 ** |
| Shenyankangfu tablet group | 28.13±2.89 ** | 24.94±2.94 ** | 27.78±0.85 ** |
| High dose group | 28.38±3.20 ** | 26.58±2.14 ** | 29.98±1.19 △ |
| Middle dosage group | 28.61±2.67 ** | 25.92±3.12 ** | 31.38±0.97 △△ |
| Low dose group | 28.48±1.86 ** | 24.82±3.59 ** | 27.72±2.61 * |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling rat serum albumin significantly increase (with the comparison of blank group,
*p<0.01), between each group of modeling group without significant difference.Treat after 14 days, each administration group effect not significantly (with the comparison of blank group,
*p<0.01).Treat after 28 days, high, the middle dosage group of the clear Zhixieli granules of kidney tonifying effect is significantly (with model group comparison
△p<0.05,
△ △p<0.01).Shenyankangfu tablet group, the clear Zhixieli granules low dose group of kidney tonifying effect not significantly (with the comparison of blank group,
*p<0.05,
*p<0.01).
2.4.4 serum creatinine dynamic change rat eye socket is got blood, measures serum creatinine.
Table 3 serum creatinine (umol/L,
n=10)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 20.33±1.86 | 22.8311.47 | 23.40±1.81 |
| Model group | 30.40±4.92 ** | 30.14±3.97 ** | 27.66±1.36 * |
| Shenyankangfu tablet group | 31.80±5.71 ** | 32.42±4.72 ** | 27.611.67 * |
| High dose group | 29.40±5.54 ** | 28.25±2.06 ** | 23.67±2.32 △△ |
| Middle dosage group | 32.2±1.92 ** | 28.7515.67 * | 24.71±2.42 △ |
| Low dose group | 31.2±8.34 * | 31.25±4.36 ** | 28.2±1.48 |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling rat blood serum creatinine significantly increase (with the comparison of blank group,
*p<0.05,
*p<0.01), between each group of modeling group without significant difference.Treat after 14 days, each administration group effect not significantly (with the comparison of blank group,
*p<0.01).Treat after 28 days, high, the middle dosage group of the clear Zhixieli granules of kidney tonifying effect is significantly (with model group comparison
△p<0.05,
△ △p<0.01).Shenyankangfu tablet group, the clear Zhixieli granules low dose group of kidney tonifying effect not significantly (with the comparison of blank group,
*p<0.05).
From above result, the clear Zhixieli granules of kidney tonifying significantly lowers twenty-four-hour urine albumen and creatinine, rising serum albumin, shenyankangfu tablet significantly reduces twenty-four-hour urine albumen, reduce serum creatinine rising trend, but effect is not remarkable, for albuminous reduction, without remarkable, improves.Two medicines are compared the clear Zhixieli granules reduction of kidney-nourishing Xue Qing Ji, the albuminous effect of Gao Xue Cheongju of Shenging is better than shenyankangfu tablet.
Therefore, the clear Zhixieli granules of kidney tonifying has good therapeutical effect to Heymann nephritis, can improve Heymann Glomerulonephritis Rats symptom, reduces twenty-four-hour urine protein quantification and serum creatinine level the serum albumin that raises.
3. the clear Zhixieli granules of kidney tonifying is for the brightic effect of rat C-BSA
3.1 experimental technique
3.1.1 the preparation of cationization bovine serum albumin (C-BSA)
(1) get 67mL anhydrous ethylenediamine (EDA) liquid, add 500mL distilled water, add again 6mol/L hydrochloric acid 350ml and adjust pH value to 4.75, be cooled to 25 ℃, stir, add natural bovine serum albumin (N-BSA) 5g to be dissolved in the solution of 25ml double distilled water, after stirring, add again 1.8g carbonization diimmonium salt hydrochlorate (EDCHCL) and maintain 25 ℃, continue to stir 2h, keep pH value 4.75, finally add 4mol/L (pH value 4.75) acetate buffer solution 30ml, cessation reaction, obtains the C-BSA solution (PI=9.2) that isoelectric point, IP improves.
(2) C-BSA solution is placed in to semi-transparent bag, with 4 ℃ of distilled water dialysis 72h (3～5h changes water once), after lyophilization, obtains BSA dry powder.Be stored in-30 ℃ standby.
(3) get above-mentioned powder, cationization bovine serum albumin, dissolves filtration sterilization before use with 0.01mol/LPH7.4PBS.
3.1.2 incomplete Freund's adjuvant preparation
Lanoline 10g, liquid paraffin 40mL, 108 ℃ of sterilization 15min; Mortar ultra violet lamp 2h adds lanoline in mortar on superclean bench, by grinding limit, lanoline mass volume ratio 1:3 limit, add liquid paraffin, is ground to all and hooks, and obtains incomplete Freund's adjuvant.Be stored in refrigerator (4 ℃) standby.
3.1.3C-BSA Nephritis Model
Get 72 of rats, adaptability is raised after 3d, collects 24h urine, and biuret colorimetry is surveyed 24h urine protein, by 24h urine albumen amount and body weight, is divided at random normal group, positive drug matched group, model group, the clear Zhixieli granules of kidney tonifying is high, in, totally six groups of end dosage groups.Pre-immunity, is dissolved in C-BSA1mg in PBS0.5mL, fully emulsified with IFA equivalent after, give rat multiple spot subcutaneous injection; Formal immunity, 8d starts, the next day tail vein injection C-BSA16mg/kg time, common 29d.Collect twenty-four-hour urine liquid, detect its twenty-four-hour urine albumen.Each is organized urine protein and significantly raises rat in the 12nd week beginning gastric infusion of experiment, every day, gastric infusion was 1 time, successive administration 28d, and blank group, model group give normal saline, positive drug group gives shenyankangfu tablet suspension, is subject to reagent group to give kidney tonifying clear Zhixieli granules extractum.Administration volume is 1mL/100g.
3.1.4IL-6 the foundation of assay method and standard curve
3.1.4.1IL-6 assay method
1) within 20 minutes, from refrigerator, take out test kit in advance, with balance room temperature.In sealing bag, take out the required lath of test, the lath of use and desiccant are not put back in pot model bag and are sealed in 4 ℃, respectively specimen and variable concentrations standard substance (0pg/ml hole reagent adding diluent) are added in respective aperture.With shrouding gummed paper, seal reacting hole, 37 ℃ of incubators are hatched 40min.
Note: IL-6 standard substance are diluted to 2000,1000,500,250,125,62.5,31.25 (pg/ml) successively.
2) wash plate 6 times, add distilled water and each 50ul of first antibody working solution (except blank).With shrouding gummed paper, seal reacting hole, 37 ℃ of incubators are hatched 20min.
3) wash plate 6 times, add enzyme labelled antibody working solution (100ul/ hole).With shrouding gummed paper, seal reacting hole, 37 ℃ of incubators are hatched 10min.
4) wash plate 6 times (concentrated cleaning solution dilutes 1:20 with distilled water), add substrate working solution 100ul/ hole, 37 ℃ of incubator dark place lucifuges are hatched 15min.
5) add stop buffer 100ul/ hole, after mixing, at once measure A value.
3.1.4.2IL-6 the foundation of standard curve
With mark Huaihe River product concentration, make abscissa, A value is made vertical coordinate, draws IL-6 standard curve, according to IL-6 level in each Zu Shang Cheongju liquid of curve calculation of mark Huaihe River.
3.2 observation index
3.2.124h urine amount and urine protein detect: respectively at (before administration) after Cheng Mo, administration is put into metabolism of rat cage by rat in the 14th, 28 days and collected 24h urine amount, and biuret method is measured urine protein content.
3.2.2BUN, GRE, total serum protein, serum albumin detect: respectively at (before administration) after Cheng Mo, when administration the 14th day and administration finish, (28d after administration) gets blood through eye socket, carries out blood biochemical detection.
3.2.3 blood serum IL-6 detects: (28d after administration) gets blood through eye socket when after film forming, (before administration) and administration finish, and application BIO-RAD680 type microplate reader completes IL-6 with double antibodies sandwich ELISA method and detects.
3.3 experimental result
3.3.1 after the formal immunity of ordinary circumstance, by immune rat, occurred that smart Zhong is dispirited in various degree, the loose mixed and disorderly tarnish of hair, captures unablely, and large loose stool is thin, the phenomenons such as ascites.After administration, model group rat lethargy, the loose tarnish of hair, captures unablely, and the thin grade in large loose stool increases the weight of gradually, and clear each group of sharp agent of shenyankangfu tablet group and kidney tonifying is than improvement, but still sees lethargy, and the loose tarnish of hair captures unablely, and large loose stool is thin.
3.3.2 urine protein dynamic change accesses urine with metabolism of rat cage, measures twenty-four-hour urine protein content.The results are shown in Table 4.
Table 424 hour urine protein quantitation (mg/kg24 hour,
n=12)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 32.4±5.24 | 16.58±6.54 | 12.2±3.35 |
| Model group | 66.8±29.95 * | 33.61±9.45 ** | 32.45±10.67 ** |
| Shenyankangfu tablet group | 101.7±32.9 ** | 21.62±7.93 △ | 15.22±6.20 △ |
| High dose group | 57.2±19.73 * | 18.13±8.95 △ | 16.76±3.65 △△ |
| Middle dosage group | 74.9±25.77 ** | 22.18±5.10 △ | 14.78±5.31 △ |
| Low dose group | 51.56±12.08 * | 24.81±4.88 * | 15.97±3.66 △△ |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling Rat 24 h urine albumen amount significantly more than normal group (
*p<0.05,
*p<0.01), between each group of modeling group without significant difference.Treat after 14 days, high, the middle dosage group of the clear Zhixieli granules of kidney tonifying, shenyankangfu tablet group effect are significantly (with model group comparison
△p<0.05), low dose group effect not significantly (with the comparison of blank group,
*p<0.05).In the time of 28 days, administration is respectively organized effect significantly (with model group comparison
△p<0.05,
△ △p<0.01), low, high dose group effect extremely significantly (with model group comparison,
△ △p<0.01).This medicine can significantly reduce urine protein.
3.3.3 creatinine dynamic change rat eye socket is got blood, measures serum creatinine.The results are shown in Table 5.
Table 5 serum creatinine (umol/L,
n=12)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 16.57±1.84 | 24±1 | 23.8±0.75 |
| Model group | 22.88±2.26 * | 27±1.94 ** | 26.2±1.17 ** |
| Shenyankangfu tablet group | 24.33±3.77 * | 24.33±1.37 △ | 23.17±2.19 △ |
| High dose group | 24.77±5.55 * | 24.33±1.22 △△ | 23.8±0.98 △ |
| Middle dosage group | 25.67±4.67 ** | 23.89±2.81 △ | 24.2±0.75 △ |
| Low dose group | 27.2±5.56 * | 24.29±1.98 △ | 24±1.41 △ |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling rat blood serum creatinine significantly increase (with the comparison of blank group,
*p<0.05,
*p<0.01), between each group of modeling group without significant difference.Treat after 14 days, each administration group effect is all significantly (with model group comparison
△p<0.05,
△ △p<0.01), high dose group more remarkable effect (with model group comparison,
△ △p<0.01).Treat after 28 days, each organize effect all significantly (
△p<0.05).This medicine can significantly reduce serum creatinine.
3.3.4 serum albumin dynamic change rat eye socket is got blood, measures serum albumin.The results are shown in Table 6.
Table 6 serum albumin (g/L,
n=12)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 35.93±0.81 | 37.3±1.08 | 35.83±0.75 |
| Model group | 34.29±1.30 * | 35.57±0.57 ** | 34.62±0.16 ** |
| Shenyankangfu tablet group | 33.4±1.15 ** | 35.6±1.26 ** | 35.24±0.38 △ |
| High dose group | 32.7±3.57 * | 36.96±1.37 △ | 35.8±0.94 △ |
| Middle dosage group | 34.23±1.53 * | 37.26±0.90 △△ | 35.76±0.96 △ |
| Low dose group | 33.56±1.82 * | 35.99±0.78 * | 32.13±3.07 * |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
Result shows, after modeling rat serum albumin significantly increase (with the comparison of blank group,
*p<0.05
*, P<0.01), between each group of modeling group without significant difference.Treat after 14 days, high, the middle dosage group of the clear Zhixieli granules of kidney tonifying effect is significantly (with model group comparison
△p<0.05,
△ △p<0.01).Treat after 28 days, shenyankangfu tablet group, high, the middle dosage group of the clear Zhixieli granules of kidney tonifying effect are all significantly (with model group comparison
△p<0.05).This medicine serum albumin that can significantly raise, effect is early than shenyankangfu tablet.
3.3.5 cholesterol dynamic change rat eye socket is got blood, measures serum cholesterol.The results are shown in Table 7.
Table 7 serum cholesterol (mmol/L,
n=12)
| Grouping | Before administration | Administration 14 days | Administration 28 days |
| Blank group | 1.78±0.13 | 1.47±0.11 | 1.35±0.07 |
| Model group | 2.36±0.42 * | 1.78±0.19 ** | 1.61±0.19 * |
| Shenyankangfu tablet group | 2.7±0.42 * | 1.82±0.29 * | 1.53±0.12 * |
| High dose group | 2.16±0.41 * | 1.84±0.32 * | 1.36±0.13 △ |
| Middle dosage group | 2.13±0.31 * | 1.55±0.09 △ | 1.40±0.11 △ |
| Low dose group | 2.26±0.38 * | 1.72±0.20 * | 1.30±0.18 △ |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison
△p<0.05,
△ △p<0.01.
After modeling, each organize cholesterolemia all significantly raise (with normal group comparison,
*p<0.05), between each group of modeling group without significant difference.While treating 14 days, in the clear Zhixieli granules of kidney tonifying dosage group effect significantly (with model group comparison,
△p<0.05).In the time of 28 days, each dosage group effect of the clear Zhixieli granules of kidney tonifying all significantly (with model group comparison,
△p<0.05).Point out this medicine can improve cholesterol rising trend, effect early than, be better than shenyankangfu tablet.
3.3.6 before and after treatment, rat blood serum IL-6 level comparison rat eye socket is got blood, measures blood serum IL-6.The results are shown in Table 8.
Table 8 respectively organize the comparison that rat IL-6 expresses (pg/mL,
)
| Grouping | n | Before administration | Administration 28 days |
| Blank group | 9 | 14.09±3.65 | 19.43±4.05 |
| Model group | 8 | 105.97±44.17 ** | 257.00±81.49 ** |
| Shenyankangfu tablet group | 8 | 305.52±195.99 ** | 140.28±102.34 △# |
| High dose group | 9 | 262.26±112.10 ** | 54.56±34.18 △## |
| Low dose group | 8 | 199.03±56.04 ** | 59.95±40.63 △# |
Note: with the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison,
△p<0.05,
△ △p<0.01; With treatment before compare,
#p<0.05,
##p<0.01.
After modeling, each organize rat blood serum IL-6 level significantly raise (with normal group comparison, P<0.01), between each group of modeling group without significant difference.In the time of 28 days, shenyankangfu tablet group, the clear Zhixieli granules high and low dose of kidney tonifying group rat blood serum IL-6 level are all lower than model group, and both relatively have significant difference (P<0.05).
Therefore, low, the high dose group of the clear Zhixieli granules of kidney tonifying can extremely significantly reduce 24h urine protein (
△ △p<0.01).High dose group effect can extremely significantly reduce creatinine (
△ △p<0.01), IL-6.Shenyankangfu tablet group and height, middle dosage group all significantly reduce serum albumin (
△p<0.05), and early than shenyankangfu tablet.Each dosage group all significantly improve cholesterol rising trend (
△p<0.05), its effect early than, be better than shenyankangfu tablet.
Originally studies confirm that, the clear Zhixieli granules of kidney tonifying has good therapeutical effect to C-BSA nephritis, can improve its symptom, reduces 24h urine protein quantitation and serum creatinine level, and rising serum albumin and improve cholesterol rising trend is wherein particularly evident with high dose group effect.
Claims (8)
1. a medicine that is used for the treatment of the damp-heat type chronic nephritis of suffering from a deficiency of the kidney, is characterized in that, the crude drug of pressing row weight portion proportioning extracts and is prepared from: Radix Astragali 20-40 part; Rhizoma Atractylodis Macrocephalae 8-12 part; Fructus Corni 8-12 part; Cortex Eucommiae 10-30 part; Rhizoma Alismatis 10-20 part; Folium Pyrrosiae 10-30 part; Herba Hedyotidis Diffusae 10-30 part; Radix Notoginseng 3-7 part.
2. be used for the treatment of as claimed in claim 1 the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney, it is characterized in that, the crude drug of pressing row weight portion proportioning extracts and is prepared from: 30 parts of the Radixs Astragali; 10 parts of the Rhizoma Atractylodis Macrocephalaes; 10 parts of Fructus Corni; 20 parts of the Cortexs Eucommiae; 15 parts of Rhizoma Alismatis; 20 parts of Folium Pyrrosiae; 20 parts of Herba Hedyotidis Diffusaes; 5 parts of Radix Notoginseng.
3. be used for the treatment of as claimed in claim 1 the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney, it is characterized in that preparation method comprises the following steps:
A) by above-mentioned parts by weight, get the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae two tastes are through extraction by steam distillation volatile oil, with beta-cyclodextrin inclusion compound;
B) by above-mentioned parts by weight, get the Radix Astragali, the Cortex Eucommiae, Rhizoma Alismatis, Folium Pyrrosiae, the Radix Notoginseng five tastes, through alcohol reflux, filter, and reclaim ethanol, concentrate to obtain alcohol extraction concentrated solution;
C) medicinal residues after the medicinal residues after step a steam distillation, b alcohol extraction and Fructus Corni are merged, through decocting, boil, filter, concentrated, cooling, add ethanol precipitate with ethanol and obtain water extract-alcohol precipitation concentrated solution; The alcohol extraction concentrated solution of water extract-alcohol precipitation concentrated solution and step b is merged, and spraying is dry, makes dry extract;
D) get the volatile oil clathrate compound of step a and the dry extract of c carries out wet granulation, dry, obtain medicine.
4. the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of as claimed in claim 3, it is characterized in that steam distillation in preparation method step a, use 6 times of water gagings of medical material weight to soak 1 hour, distill and within 8 hours, extract volatile oil, volatile oil adds 6 times of weight beta-schardinger dextrin-s, adopts 40 ℃ of electric stirrings of saturated water solution method, and mixing speed is 120r/min, stir and carry out enclose after 1.5 hours, 40 ℃ of vacuum dryings of clathrate.
5. the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of as claimed in claim 3, it is characterized in that alcohol reflux in preparation method step b, institute's alcohol adding amount is 12 times of decoction pieces gross weight, ethanol volumetric concentration is 70%, minute three reflux, extract,, each 2 hours, merge extractive liquid,, filter, decompression filtrate recycling ethanol, is concentrated into without alcohol taste.
6. the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of as claimed in claim 3, it is characterized in that in preparation method step c, through decocting, boil, amount of water is 12 times of decoction pieces gross weight, divide secondary to decoct, each 2 hours, merge decocting liquid, filter, when filtrate is concentrated into 50 ℃, relative density is 1.05～1.08, cooling, add ethanol to alcohol content and be no more than 50%, stir evenly, place 48 hours, filter, filtrate recycling ethanol, while being concentrated into 50 ℃ with above-mentioned alcohol extraction concentrated solution merging, relative density is 1.10～1.15, add dextrin appropriate, in import pathogenic wind-warm, it is 165～175 ℃, under 85～90 ℃ of conditions of outlet pathogenic wind-warm, be spray dried to dry extract.
7. the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney that is used for the treatment of as claimed in claim 3, it is characterized in that in preparation method steps d, get and in step a volatile oil clathrate compound and step c, get that dry extract adds appropriate Icing Sugar, dextrin mixes and carries out wet granulation, dry, obtain medicine, dosage form is tablet or granule or hard capsule.
8. be used for the treatment of as claimed in claim 1 the application that the damp-heat type chronic nephritis medicine of suffering from a deficiency of the kidney is suffered from a deficiency of the kidney in damp-heat type chronic nephritis medicine in preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206252.XA CN103948754B (en) | 2014-05-15 | 2014-05-15 | Drug for treating renal-deficiency humid-heat type chronic nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206252.XA CN103948754B (en) | 2014-05-15 | 2014-05-15 | Drug for treating renal-deficiency humid-heat type chronic nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103948754A true CN103948754A (en) | 2014-07-30 |
| CN103948754B CN103948754B (en) | 2017-02-01 |
Family
ID=51326195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410206252.XA Active CN103948754B (en) | 2014-05-15 | 2014-05-15 | Drug for treating renal-deficiency humid-heat type chronic nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948754B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740130A (en) * | 2015-04-25 | 2015-07-01 | 青岛辰达生物科技有限公司 | Pharmaceutical composition for treating chronic nephritis |
| CN104840646A (en) * | 2015-06-09 | 2015-08-19 | 徐艳 | Medicine for treating chronic nephritis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1509739A (en) * | 2002-12-23 | 2004-07-07 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for chronic primary glomerulonephritis and its preparation and quality control |
| CN1931306A (en) * | 2005-08-22 | 2007-03-21 | 杨文龙 | Chinese medicine soft capsule for treating urinary system diseases and its prepn process |
-
2014
- 2014-05-15 CN CN201410206252.XA patent/CN103948754B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1509739A (en) * | 2002-12-23 | 2004-07-07 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for chronic primary glomerulonephritis and its preparation and quality control |
| CN1931306A (en) * | 2005-08-22 | 2007-03-21 | 杨文龙 | Chinese medicine soft capsule for treating urinary system diseases and its prepn process |
Non-Patent Citations (3)
| Title |
|---|
| 吴金珠: ""益肾清利颗粒干预慢性肾小球肾炎肾虚湿热证的临床观察与动物实验"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 时振声主编: "《中国医药科技出版社》", 31 January 1997 * |
| 赵霞: """益肾清利剂"治疗慢性肾炎肾虚"", 《江苏中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740130A (en) * | 2015-04-25 | 2015-07-01 | 青岛辰达生物科技有限公司 | Pharmaceutical composition for treating chronic nephritis |
| CN104840646A (en) * | 2015-06-09 | 2015-08-19 | 徐艳 | Medicine for treating chronic nephritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103948754B (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690741A (en) | Pharmaceutical composition for treating gout and gouty arthritis | |
| CN104758736A (en) | Blood-glucose-reducing traditional Chinese medicine composition and preparation method thereof | |
| CN109045229A (en) | The Chinese medicine composition and preparation method thereof for treating urarthritis | |
| CN103705687A (en) | Traditional Chinese medicinal composition for preventing and treating early chronic renal failure and preparation method thereof | |
| CN103191298A (en) | Traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease and preparation method thereof | |
| CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN103948754B (en) | Drug for treating renal-deficiency humid-heat type chronic nephritis | |
| CN106074810A (en) | A kind of three wonderful capsules and preparation method thereof | |
| CN101584786A (en) | Chinese materia medica preparation for treating chronic renal insufficiency | |
| CN114917310B (en) | Traditional Chinese medicine for treating 3-5 stages of chronic kidney disease and preparation method thereof | |
| CN103638135B (en) | Pure and impure kidney-tonifying capsule | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN106039131B (en) | A kind of compound Chinese medicinal preparation and its preparation method and application treated IgA nephrosis and merge hyperuricemia | |
| CN101732652A (en) | Chinese patent medicament for treating ulcerative colitis | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN110064016B (en) | Traditional Chinese medicine composition for regulating immune state of chronic kidney disease and preparation method thereof | |
| CN103690768A (en) | Creeping liriope-figwort-milkvetch root soft capsules and preparation method thereof | |
| CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
| CN102641402A (en) | Preparation and quality control method of traditional Chinese medicine compound preparation for treating nephritis | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN106668431B (en) | A Chinese medicinal composition with effects of warming kidney and invigorating qi, and its preparation method and application | |
| CN115645493B (en) | Traditional Chinese medicine preparation for treating chronic kidney disease stage 3 and preparation method thereof | |
| CN108310304A (en) | The prescription preparation method of chronic nephritis is treated in a kind of inducing diuresis with bland drug ruling by law |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |